We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Fusion Pharmaceuticals Inc. Common Shares in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 114 → 0 (-114)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

100% less capital invested

Capital invested by funds: $1.47B → $0 (-$1.47B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 112

Holders
–
Holders Change
-114
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
112
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$230M
2
PA
Perceptive Advisors
New York
-$146M
3
APM
Avidity Partners Management
Texas
-$139M
4
DM
Deerfield Management
New York
-$136M
5
Fidelity International
Fidelity International
Bermuda
-$89.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
76
VOYA Investment Management
Georgia
– -$646K -30,280 Closed
YCM
77
Yakira Capital Management
Connecticut
– -$644K -30,200 Closed
GS
78
GTS Securities
New York
– -$620K -29,095 Closed
VF
79
Virtu Financial
New York
– -$616K -28,917 Closed
Citigroup
80
Citigroup
New York
– -$539K -25,268 Closed
JC
81
JBF Capital
Colorado
– -$533K -25,000 Closed
MTCM
82
Mint Tower Capital Management
Netherlands
– -$533K -25,000 Closed
Allianz Asset Management
83
Allianz Asset Management
Germany
– -$443K -20,800 Closed
NIM
84
NEOS Investment Management
Connecticut
– -$400K -18,774 Closed
HF
85
HRT Financial
New York
– -$381K -17,911 Closed
ProShare Advisors
86
ProShare Advisors
Maryland
– -$376K -17,623 Closed
BCM
87
Beryl Capital Management
California
– -$345K -16,191 Closed
TAM
88
Titleist Asset Management
Texas
– -$342K -16,050 Closed
FLC
89
Fifth Lane Capital
Texas
– -$341K -16,000 Closed
Northern Trust
90
Northern Trust
Illinois
– -$298K -13,983 Closed
CUAMC
91
China Universal Asset Management Company
China
– -$297K -13,920 Closed
ASRS
92
Arizona State Retirement System
Arizona
– -$255K -11,939 Closed
Two Sigma Advisers
93
Two Sigma Advisers
New York
– -$249K -11,700 Closed
GI
94
GAMCO Investors
Connecticut
– -$244K -11,450 Closed
CM
95
Crystalline Management
Canada
– -$239K -11,207 Closed
BCM
96
Bluefin Capital Management
New York
– -$213K -10,000 Closed
GCM
97
Greenland Capital Management
New York
– -$213K -10,000 Closed
Teacher Retirement System of Texas
98
Teacher Retirement System of Texas
Texas
– -$206K -9,669 Closed
CL
99
CSS LLC
Illinois
– -$203K -9,500 Closed
Barclays
100
Barclays
United Kingdom
– -$185K -8,683 Closed
1 2 3
4
5

FUSN Hedge Fund Activity: Q2 2024 in Review

0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2024, worth a combined $0 — down 100% from $1.47B a quarter earlier.

Sellers outnumbered buyers: 112 funds closed out of FUSN and 0 opened new positions — a net loss of 112 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Federated Hermes, exiting entirely with an estimated $230M sold.

  • 0 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2024, down from 114 in Q1 2024.
  • Funds reported $0 of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2024 and 112 closed out, a net change of -112 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2024 was Federated Hermes, an estimated $230M sold.

Based on aggregated 13F filings for Q2 2024.